

Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Oxytetracycline Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the s	safe	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Aerosols, Category 2

Eye irritation, Category 2 Skin sensitisation, Category 1 Reproductive toxicity, Category 1A Specific target organ toxicity - single exposure, Category 3 Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1 H223: Flammable aerosol.
H229: Pressurised container: May burst if heated.
H319: Causes serious eye irritation.
H317: May cause an allergic skin reaction.
H360D: May damage the unborn child.
H336: May cause drowsiness or dizziness.

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version 9.0	Revision Date: 28.09.2024	SDS Number: 673928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
Haza	rd pictograms		
Signa	l word	: Danger	
Haza	rd statements	H229 Pressuris H317 May cau H319 Causes H336 May cau H360D May dan	ble aerosol. sed container: May burst if heated. se an allergic skin reaction. serious eye irritation. se drowsiness or dizziness. nage the unborn child. c to aquatic life with long lasting effects.
Preca	utionary statements	Prevention:	
		P210 Keep aw flames and other P211 Do not s P251 Do not p P273 Avoid rel	pecial instructions before use. ay from heat, hot surfaces, sparks, open ignition sources. No smoking. pray on an open flame or other ignition source. ierce or burn, even after use. ease to the environment. otective gloves/ protective clothing/ eye protec- ion.
		Response: P391 Collect s	pillage.
		Storage: P410 + P412 F	Protect from sunlight. Do not expose to tem- ding 50 °C/ 122 °F.

Hazardous components which must be listed on the label:

Butane Propan-2-ol Isobutane oxytetracycline

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May displace oxygen and cause rapid suffocation.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Butane	106-97-8 203-448-7 601-004-00-0	Flam. Gas 1A; H220 Press. Gas Liquefied gas; H280 STOT SE 3; H336	>= 20 - < 30
Propan-2-ol	67-63-0 200-661-7 603-117-00-0	Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336	>= 10 - < 20
Isobutane	75-28-5 200-857-2 601-004-00-0	Flam. Gas 1A; H220 Press. Gas Liquefied gas; H280 STOT SE 3; H336	>= 10 - < 20
Propane	74-98-6 200-827-9 601-003-00-5	Flam. Gas 1A; H220 Press. Gas Liquefied gas; H280 STOT SE 3; H336	>= 10 - < 20
oxytetracycline	79-57-2 201-212-8	Skin Sens. 1A; H317 Repr. 1A; H360D Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 2,5 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

: In the case of accident or if you feel unwell, seek medical ad-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 9.0	Revision Date: 28.09.2024	SDS Number: 673928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016		
		vice immediat When sympto advice.	ely. ms persist or in all cases of doubt seek medical		
Protection of first-aiders		and use the re	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
If inhaled		If not breathin If breathing is	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.		
In case of skin contact		Remove conta Get medical a Wash clothing	atact, immediately flush skin with plenty of water. aminated clothing and shoes. ttention. g before reuse. ean shoes before reuse.		
In case of eye contact		for at least 15	remove contact lens, if worn.		
If swallowed		Get medical a	DO NOT induce vomiting. ttention. horoughly with water.		
4.2 Most i	mportant symptoms	s and effects, both a	cute and delayed		
Symp	otoms	: Gastrointestin	al disturbance		
Risks		Causes serior May cause dr	a allergic skin reaction. us eye irritation. owsiness or dizziness. the unborn child.		
		Gas reduces	oxygen available for breathing.		
	tion of any immedia	te medical attention	and special treatment needed		
4.3 Indica	, ,		natically and supportively.		

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing	:	None known.



Oxytetracycline Formulation

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

media

5.2 Special hazards arising from the substance or mixture

	Specific hazards during fire- fighting	:	Flash back possible over considerable distance. Vapours may form explosive mixtures with air. Exposure to combustion products may be a hazard to health. If the temperature rises there is danger of the vessels bursting due to the high vapor pressure.
	Hazardous combustion prod- ucts	:	Carbon oxides
5.3	Advice for firefighters		
	Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
	Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	 Evacuate personnel to safe areas. Remove all sources of ignition. Ventilate the area. Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
----------------------	---

6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
---------------------------	---	--

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Non-sparking tools should be used.
	Soak up with inert absorbent material.
	Suppress (knock down) gases/vapours/mists with a water
	spray jet.
	For large spills, provide dyking or other appropriate contain-
	ment to keep material from spreading. If dyked material can



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016
		Clean up rema bent. Local or nation posal of this ma employed in the mine which reg Sections 13 an	bre recovered material in appropriate container. ining materials from spill with suitable absor- al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- gulations are applicable. Id 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling				
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.			
Local/Total ventilation	 If sufficient ventilation is unavailable, use with local exhaust ventilation. If advised by assessment of the local exposure potential, use only in an area equipped with explosion-proof exhaust ventila- tion. 			
Advice on safe handling	 Do not get on skin or clothing. Avoid breathing spray. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. Do not spray on an open flame or other ignition source. 			
Hygiene measures	 If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. 			

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	:	Store locked up. Keep tightly closed. Keep in a cool, well- ventilated place. Store in accordance with the particular na- tional regulations. Do not pierce or burn, even after use. Keep cool. Protect from sunlight.
Advice on common storage	:	Do not store with the following product types: Self-reactive substances and mixtures

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.07.2024
9.0		673928-00022	Date of first issue: 12.05.2016
			s ds ds s stances and mixtures d mixtures, which in contact with water, emit

7.3 Specific end use(s)

Specific use(s)

: No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Butane	106-97-8	TWA	250 ppm 600 mg/m3	FOR-2011- 12-06-1358
Propan-2-ol	67-63-0	TWA	100 ppm 245 mg/m3	FOR-2011- 12-06-1358
Propane	74-98-6	TWA	500 ppm 900 mg/m3	FOR-2011- 12-06-1358
oxytetracycline	79-57-2	TWA	500 µg/m3 (OEB 2)	Internal
	Further infor	Further information: DSEN		
		Wipe limit	100 µg/100 cm²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propan-2-ol	Fresh water	140,9 mg/l
	Marine water	140,9 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version 9.0	Revision Date: 28.09.2024	SDS Number: 673928-00022	Date of last issue: 0 Date of first issue: 1	
Ш		Intermittent us	se/release	140,9 mg/l
	Sewage treatmen		ment plant	2251 mg/l
		Fresh water s	ediment	552 mg/kg dry weight (d.w.)
		Marine sedim	ent	552 mg/kg dry weight (d.w.)
		Soil		28 mg/kg dry weight (d.w.)
		Oral (Second	ary Poisoning)	160 mg/kg food

8.2 Exposure controls

Personal protective equipment

Hand protection

Remarks	:	Take note that the product is flammable, which may impact the selection of hand protection.
Claim and hady protection		
Skin and body protection		Skin should be washed after contact.
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo-
		sure assessment demonstrates exposures outside the rec-
		ommended guidelines, use respiratory protection.
		Equipment should conform to NS EN 137
Filter type	:	Self-contained breathing apparatus

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	Aerosol containing a liquefied gas
Colour	:	blue
Odour	:	solvent-like
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Flammable aerosol.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	9,5 %(V)
Lower explosion limit / Lower flammability limit	:	1,8 %(V)
Flash point	:	-80 °C

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Vers 9.0	sion	Revision Date: 28.09.2024		S Number: 3928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
	Auto-ię	gnition temperature	:	No data available	e
	Decom	nposition temperature	:	No data availabl	e
	рН		:	No data availabl	e
	Viscos Vis	ity cosity, kinematic	:	No data availabl	e
		lity(ies) ter solubility	:	No data available	e
		on coefficient: n- l/water	:	No data available	e
	Vapou	r pressure	:	No data available	e
	Relativ	ve density	:	No data available	e
	Densit	у	:	0,92 g/cm ³	
	Relativ	ve vapour density	:	No data available	e
		e characteristics ticle size	:	No data availabl	e
9.2	Other i	nformation			
	Explos	sives	:	Not explosive	
	Oxidiz	ing properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapo	ration rate	:	No data availabl	e

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	 Flammable aerosol. Vapours may form explosive mixture with air. If the temperature rises there is danger of the vessels bursting due to the high vapor pressure.
	due to the high vapor pressure.
	Can react with strong oxidizing agents.

10.4 Conditions to avoid



Version 9.0	Revision Date: 28.09.2024	SDS Nu 673928		Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
Cond	litions to avoid	: Hea	at, flames an	d sparks.
	mpatible materials rials to avoid	: Oxi	dizing agent	S
	ardous decomposition azardous decomposition	-		
SECTION	N 11: Toxicological i	nformati	on	
11.1 Infor	mation on hazard clas	ses as de	fined in Re	gulation (EC) No 1272/2008
Inforr expo	nation on likely routes o sure	Skir Inge	lation contact stion contact	
	e toxicity lassified based on avail	able inforr	nation.	
<u>Com</u>	ponents:			
Buta	ne:			
Acute	e inhalation toxicity	Exp Test	0 (Rat): 5700 osure time: 1 atmosphere narks: Based	5 min
Prop	an-2-ol:			
	e oral toxicity	: LD5	0 (Rat): > 5.0	000 mg/kg
Acute	e inhalation toxicity	Exp	0 (Rat): > 25 osure time: 6 atmosphere	5 h
Acute	e dermal toxicity	: LD5	0 (Rabbit): >	5.000 mg/kg
Isobi	utane:			
Acute	e inhalation toxicity	Exp	0 (Rat): 5700 osure time: 1 atmosphere	5 min
Prop	ane:			
Acute	e inhalation toxicity	Exp	0 (Rat): > 80 osure time: 1 atmosphere	5 min
-	etracycline: e oral toxicity	: LD5	0 (Rat): 4.80	0 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 9.0	Revision Date: 28.09.2024		S Number: 3928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
			LD50 (Mouse): 2.2 Remarks: Evidenc	240 mg/kg ce of phototoxicity was observed
Acute	inhalation toxicity	:	Remarks: No data	available
Acute	e dermal toxicity	:	Remarks: No data	available
	e toxicity (other routes of nistration)	:	LD50 (Rat): 4.840 Application Route:	
			LD50 (Mouse): 3.5 Application Route:	
-	corrosion/irritation lassified based on availa	ble	information.	
Com	oonents:			
	an-2-ol:			
Speci Resu		:	Rabbit No skin irritation	
Rema		:	No data available	
	us eye damage/eye irri es serious eye irritation.	tatio	on	
	oonents:			
Propa	an-2-ol:			
Speci Resu		:	Rabbit Irritation to eyes, r	reversing within 21 days
oxyte Rema	etracycline: arks	:	No data available	
Resp	iratory or skin sensitis	atio	n	
	sensitisation cause an allergic skin rea	ictio	n.	
-	iratory sensitisation lassified based on availa	ble	information.	
<u>Com</u>	oonents:			
Test	an-2-ol: Type sure routes	:	Buehler Test Skin contact	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 9.0	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.07.2024673928-00022Date of first issue: 12.05.2016
Spec Meth Resu	od	 Guinea pig OECD Test Guideline 406 negative
oxyte Test Resu		: Human repeat insult patch test (HRIPT) : Sensitiser
Not c	n cell mutagenicity lassified based on ava	ilable information.
	ponents:	
Buta Geno	ne: toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
		Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative
Geno	toxicity in vivo	 Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials
Prop	an-2-ol:	
	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Geno	toxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative
Isobu	utane:	
Geno	toxicity in vitro	 Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials Propane: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: : Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Result: negative Genotoxicity in vitro : Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: negative Genotoxicity in vitro : Test Type: Chromosomal aberration Result: negative Genotoxicity in vitro : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Genotoxicity in vivo : Test Type: in vivo assay Species: Mouse Cell type: ion viso assay Species: Mouse Application Route: Oral Result: negative Genotoxicity in vivo : Test Type: in vivo assay Species: Mouse Application Route: Oral Result: negative Genotoxicity in vivo : Test	/ersion).0	Revision Date: 28.09.2024	-	9S Number: 3928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials Propane: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Genotoxicity in vitro : Test Type: Marmalian erythrocyte micronucleus test (in vice cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: Genotoxicity in vitro : Test Type: Marmalian erythrocyte micronucleus test (in vice cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation: <td></td> <td></td> <td></td> <td></td> <td></td>					
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: : Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Genotoxicity in vitro : Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: positive Test Type: Sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Genotoxicity in vivo : Test Type: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ	Genc	otoxicity in vivo	:	cytogenetic ass Species: Rat Application Rou Method: OECD Result: negative	ay) ite: inhalation (gas) Test Guideline 474 e
Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Result: negative Result: negative Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: positive Test Type: Sister chromatid exchange assay Test Type: Chromosomal aberration Result: equivocal Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Cell type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: equivocal Test Type: in vivo assay Species: Mouse	Prop	ane:			
cytogenetic assay) Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials oxytetracycline: Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: positive Test Type: sister chromatid exchange assay Test Type: Sister chromatid exchange assay Test Type: Chromosomal aberration Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Cell type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ			:	Result: negative	9
Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: positive Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: equivocal Genotoxicity in vivo : Test Type: Chromosomal aberration Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Test Type: in vivo assay Species: Mouse Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ	Genc	otoxicity in vivo	:	cytogenetic ass Species: Rat Application Rou Method: OECD Result: negative	ay) ite: inhalation (gas) Test Guideline 474 e
Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test) Result: negative Test Type: Mouse Lymphoma Metabolic activation: Metabolic activation Result: positive Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: equivocal Genotoxicity in vivo : Test Type: Chromosomal aberration Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Test Type: in vivo assay Species: Mouse Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ	oxvte	etracvcline:			
Metabolic activation: Metabolic activation Result: positive Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: equivocal Test Type: Chromosomal aberration Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Cell type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ	-	-	:		
Test system: Chinese hamster ovary cells Result: equivocal Test Type: Chromosomal aberration Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Cell type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ				Metabolic activa	ation: Metabolic activation
Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ				Test system: Cl	hinese hamster ovary cells
Species: Mouse Cell type: Bone marrow Application Route: Oral Result: equivocal Test Type: in vivo assay Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ					
Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity- As- : Weight of evidence does not support classification as a germ	Geno	otoxicity in vivo	:	Species: Mouse Cell type: Bone Application Rou	e marrow ite: Oral
				Species: Mouse Application Rou	e ite: Intraperitoneal injection
0			:		nce does not support classification as a germ

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

Π

Carcinogenicity

Not classified based on available information.

Components:

Propan-2-ol: Species Application Route Exposure time Method Result	:	Rat inhalation (vapour) 104 weeks OECD Test Guideline 451 negative
oxytetracycline:		
Species Application Route Exposure time Result	:	Mouse Oral 104 weeks negative
Species Application Route Exposure time Result Target Organs Remarks		Rat Oral 103 weeks equivocal Adrenal gland, Pituitary gland The mechanism or mode of action may not be relevant in hu- mans.
Carcinogenicity - Assess- ment		Weight of evidence does not support classification as a car- cinogen
Reproductive toxicity		
May damage the unborn child		
<u>Components:</u>		
Butane:		
Effects on fertility		Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 422 Result: negative
Effects on foetal develop- ment		Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: inhalation (gas) Method: OECD Test Guideline 422 Result: negative

Propan-2-ol:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 9.0	Revision Date: 28.09.2024	SDS Number: 673928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
Effect	ts on fertility	Species: Rat	vo-generation reproduction toxicity study oute: Ingestion ve
Effect ment	ts on foetal develop-	Species: Rat	nbryo-foetal development oute: Ingestion ve
Isobu	itane:		
	ts on fertility	reproduction/c Species: Rat Application Ro	ombined repeated dose toxicity study with the developmental toxicity screening test oute: inhalation (gas) D Test Guideline 422 ve
Effect ment	ts on foetal develop-	reproduction/c Species: Rat Application Ro	mbined repeated dose toxicity study with the developmental toxicity screening test oute: inhalation (gas) D Test Guideline 422 ve
Propa	ane:		
	ts on fertility	reproduction/c Species: Rat Application Ro	mbined repeated dose toxicity study with the developmental toxicity screening test pute: inhalation (gas) D Test Guideline 422 ve
Effect ment	ts on foetal develop-	reproduction/c Species: Rat Application Ro	mbined repeated dose toxicity study with the developmental toxicity screening test pute: inhalation (gas) D Test Guideline 422 ve
II OXVte	etracycline:		
	ts on fertility	Species: Rat Application Ro Fertility: NOAI Result: No eff	vo-generation reproduction toxicity study oute: Oral EL: 18 mg/kg body weight ects on fertility, No effect on reproduction capac- ant adverse effects were reported
Effect ment	ts on foetal develop-	: Test Type: En Species: Rat Application Ro	nbryo-foetal development oute: Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version Revision Date: 9.0 28.09.2024		SDS Number: 673928-00022		Date of last issue: 06.07.2024 Date of first issue: 12.05.2016	
				oxicity: LOAEL: 48 mg/kg body weight lantation loss., Skeletal malformations	
			Species: Rat Application Rou General Toxicity Embryo-foetal to Result: No terate	v Maternal: LOAEL: 1.200 mg/kg body weight oxicity: NOAEL: 1.500 mg/kg body weight	
			Species: Mouse Application Rou General Toxicity Embryo-foetal to Result: No terate	te: Oral / Maternal: LOAEL: 1.325 mg/kg body weight pxicity: NOAEL: 2.100 mg/kg body weight	
			Species: Rabbit Application Rou Embryo-foetal to	ryo-foetal development te: Intramuscular oxicity: LOAEL: 41,5 mg/kg body weight lantation loss., No foetal abnormalities	
			Species: Dog Application Rou Embryo-foetal to	ryo-foetal development te: Intramuscular oxicity: LOAEL: 20,75 mg/kg body weight and visceral variations, Postimplantation loss.	
Repro sessn	oductive toxicity - As- nent	:	Positive evidend human epidemid	e of adverse effects on development from blogical studies.	
May o	- single exposure cause drowsiness or diz conents:	zzine	SS.		
Butar Asses Rema	ssment	:		vsiness or dizziness. rom similar materials	
Propa Asses	an-2-ol: ssment	:	May cause drow	vsiness or dizziness.	
Isohu	itane:				
Asses		:	May cause drow	vsiness or dizziness.	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 9.0	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.07.2024673928-00022Date of first issue: 12.05.2016					
Prop Asse	ane: ssment	: May cause drowsiness or dizziness.					
	STOT - repeated exposure Not classified based on available information.						
Repe	ated dose toxicity						
Com	ponents:						
Buta	ne:						
	EL cation Route sure time	 Rat >= 9000 ppm inhalation (gas) 6 Weeks OECD Test Guideline 422 					
Prop	an-2-ol:						
Spec NOA Appli	ies	: Rat : 12,5 mg/l : inhalation (vapour) : 104 Weeks					
Isobu	utane:						
	EL cation Route sure time	 Rat >= 9000 ppm inhalation (gas) 6 Weeks OECD Test Guideline 422 					
Prop	ane:						
Spec NOA Appli	ies EL cation Route sure time	 Rat 7,214 mg/l inhalation (gas) 6 Weeks OECD Test Guideline 422 					
oxyte	etracycline:						
Spec LOAE Appli Expo	ies EL cation Route sure time et Organs	 Rat 198 mg/kg Oral 13 Weeks Bone No significant adverse effects were reported 					
Expo		: Mouse : 7.990 mg/kg : Oral : 13 Weeks : Bone					
		17 / 26					

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version 9.0	Revision Date: 28.09.2024	SDS Number: 673928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016
Rema	arks	: No significant	adverse effects were reported
Spec NOA LOAE Appli Expo Targe Rema	EL EL cation Route sure time et Organs	: Dog : 125 mg/kg : 250 mg/kg : Oral : 12 Months : Testis : Significant to>	ricity observed in testing
Spec NOA LOAE Appli Expo Targe	EL	: Rat : 40 mg/kg : 100 mg/kg : Intraperitonea : 14 Days : Kidney	1
-	ration toxicity lassified based on ava	ilable information	
	mation on other haza		
Endo	ocrine disrupting pro	perties	
Prod Asse	<u>uct:</u> ssment	ered to have e REACH Articl	e/mixture does not contain components consid- endocrine disrupting properties according to e 57(f) or Commission Delegated regulation 00 or Commission Regulation (EU) 2018/605 at o or higher.
Expe	rience with human e	xposure	
<u>Com</u>	ponents:		
ovit	otracycline		

oxytetracycline:

Ingestion

Symptoms: Gastrointestinal disturbance, tooth discoloration Remarks: May cause birth defects.

SECTION 12: Ecological information

:

12.1	Toxicity	/
------	----------	---

Components:		
Propan-2-ol:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10.000 mg/l Exposure time: 24 h



Version 9.0	Revision Date: 28.09.2024		OS Number: 3928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016	
Toxicit	Toxicity to microorganisms		EC50 (Pseudomonas putida): > 1.050 mg/l Exposure time: 16 h		
oxytet	racycline:				
Toxicit	Toxicity to fish		LC50 (Oryzias latipes (Japanese medaka)): 110 mg/l Exposure time: 96 h Method: OECD Test Guideline 203		
	y to daphnia and other c invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te		
			EC50 (Daphnia m Exposure time: 48 Method: OECD Te		
Toxicit plants	y to algae/aquatic	:	EC50 (Anabaena) Exposure time: 72		
			NOEC (Anabaena Exposure time: 72		
M-Fact icity)	tor (Acute aquatic tox-	:	10		
Toxicit	y to microorganisms	:	EC50 : 17,9 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition	
			NOEC : 0,2 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition	
M-Fact toxicity	tor (Chronic aquatic ′)	:	10		
12.2 Persis	stence and degradabil	ity			
Comp	onents:				
Butan	e:				
Biodeg	gradability	:	Result: Readily bio Remarks: Based of	odegradable. on data from similar materials	
Propa	n-2-ol:				
Biodeg	gradability	:	Result: rapidly de	gradable	
BOD/C	COD	:	BOD: 1,19 (BOD5 COD: 2,23))	



Version 9.0	Revision Date: 28.09.2024	-	DS Number: 73928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016		
			BOD/COD: 53 %			
Isobut	tane:					
Biodegradability		:	Result: Readily b Remarks: Based	iodegradable. on data from similar materials		
Propa	ne:					
Biodeg	gradability	:		Result: Readily biodegradable. Remarks: Based on data from similar materials		
12.3 Bioac	cumulative potential					
<u>Comp</u>	onents:					
Butan	e:					
Partitic octanc	on coefficient: n- bl/water	:	log Pow: 2,89			
	n-2-ol:					
Partitic	on coefficient: n- bl/water	:	log Pow: 0,05			
Isobut						
Partitic	on coefficient: n- bl/water	:	log Pow: 2,8			
Propa Partitic octanc	on coefficient: n-	:	log Pow: 2,36			
12.4 Mobil i No dat	ity in soil ta available					
12.5 Resul	ts of PBT and vPvB a	sse	ssment			
Produ	ct:					
Asses		:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of		
12.6 Endoo	12.6 Endocrine disrupting properties					
<u>Produ</u>	<u>ct:</u>					
Asses	sment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.		



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Please ensure aerosol cans are sprayed completely empty (including propellant) Empty containers should be taken to an approved waste han- dling site for recycling or disposal. Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or ex- pose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

	ADN	:	UN 1950	
	ADR	:	UN 1950	
	RID	:	UN 1950	
	IMDG	:	UN 1950	
	ΙΑΤΑ	:	UN 1950	
14.2	2 UN proper shipping name			
	ADN	:	AEROSOLS	
	ADR	:	AEROSOLS	
	RID	:	AEROSOLS	
	IMDG	:	AEROSOLS (oxytetracycline)	
	ΙΑΤΑ	:	Aerosols, flammable	
14.3	B Transport hazard class(es)			
			Class	Subsidiary risks
	ADN	:	2	2.1
	ADR	:	2	2.1
	RID	:	2	2.1

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline Formulation

Version 9.0	Revision Date: 28.09.2024		OS Number: 3928-00022	Date of last issue: 06.07.2024 Date of first issue: 12.05.2016		
IMD	C		2.1			
IAT		•	2.1			
		•	2.1			
	king group					
	king group ssification Code	:	Not assigned by 5F 2.1	regulation		
ADR Packing group : Classification Code : Labels : Tunnel restriction code :		:	Not assigned by 5F 2.1 (D)	2.1		
Clas	king group ssification Code ard Identification Number	:	Not assigned by 5F 23 2.1	regulation		
Lab	king group	:	Not assigned by 2.1 F-D, S-U	regulation		
Pac airci Pac	king instruction (LQ) king group	:	203 Y203 Not assigned by Flammable Gas	regulation		
Pac ger Pac	A (Passenger) king instruction (passen- aircraft) king instruction (LQ) king group els	:	203 Y203 Not assigned by Flammable Gas	regulation		
	vironmental hazards	•				
ADI						
	ironmentally hazardous	:	yes			
ADI Env	R ironmentally hazardous	:	yes			
RID		:	yes			
IMD	-	:	yes			
	ecial precautions for use	r				
	•					

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)		
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parlian	nent	and of the Council on the control of

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

P3a	FLAMMABLE AEROSOLS	Quantity 1 150 t	Quantity 2 500 t
E1	ENVIRONMENTAL HAZARDS	100 t	200 t
18	Liquefied flammable gases (including LPG) and natural gas	50 t	200 t

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements H220 H225 H280 H317 H319 H336 H360D H400 H410		Extremely flammable gas. Highly flammable liquid and vapour. Contains gas under pressure; may explode if heated. May cause an allergic skin reaction. Causes serious eye irritation. May cause drowsiness or dizziness. May damage the unborn child. Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.
Full text of other abbreviation	าร	
Aquatic Acute Aquatic Chronic Eye Irrit. Flam. Gas Flam. Liq. Press. Gas Repr. Skin Sens. STOT SE FOR-2011-12-06-1358 FOR-2011-12-06-1358 / TWA		Short-term (acute) aquatic hazard Long-term (chronic) aquatic hazard Eye irritation Flammable gases Flammable liquids Gases under pressure Reproductive toxicity Skin sensitisation Specific target organ toxicity - single exposure Norway. Occupational Exposure limits Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification procedure:

Classification of the mixture:

Aerosol 2	H223, H229	Based on product data or assessment
Eye Irrit. 2	H319	Calculation method
Skin Sens. 1	H317	Calculation method
Repr. 1A	H360D	Calculation method
STOT SE 3	H336	Calculation method
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.



Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	673928-00022	Date of first issue: 12.05.2016

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN